Greenwich Lifesciences, Inc. (GLSI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Greenwich Lifesciences, Inc. is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy designed to prevent breast cancer recurrence. The company is currently conducting its Phase III clinical trial, Flamingo-01, and has no commercial revenue. It is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(4,025,278) | $(7,283,640) | $(5,079,877) |
| Loss Per Share (Basic/Diluted) | $(0.30) | $(0.55) | $(0.39) |
| Operating Expenses | $4,045,953 | $7,328,285 | $5,198,605 |
| Cash and Equivalents (End of Period) | $3,125,101 | $3,125,101 | $7,224,875 |
| Net Cash Used in Operating Activities | N/A | $(4,067,557) | $(2,830,405) |
| Net Cash Provided by Financing Activities | N/A | $3,100,668 | $3,065,856 |
Liquidity & Debt: As of June 30, 2025, total current liabilities were $1,685,609, primarily consisting of accounts payable and accrued interest ($1,296,476) and deferred compensation to related parties ($306,281). The company has no long-term debt but relies on equity financing and related party support.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2025, increased by approximately $2.2 million (43%) compared to the same period in 2024.
- Rising Expenses: Research and Development (R&D) expenses increased by 36% ($1.6 million) year-over-year, and General and Administrative (G&A) expenses increased by 75% ($0.5 million). Management attributes these increases primarily to new stock option grants and higher clinical trial costs.
- Cash Burn: Cash reserves decreased by approximately $967,000 during the first half of 2025, compared to an increase of $235,000 in the same period in 2024.
- Financing Activity: The company raised approximately $3.1 million in net proceeds through At-The-Market (ATM) offerings in the first half of 2025, compared to $566,000 in the first half of 2024.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the company's ability to continue as a going concern is in substantial doubt due to recurring net losses and negative operating cash flows. Continued operations depend on obtaining additional capital.
- Clinical Progress: The company is expanding the Flamingo-01 Phase III trial into Europe, with plans to open up to 150 sites globally.
- Capital Raising: Management expects to continue incurring significant expenses and losses. Future funding is expected to come from equity or debt sales, though no assurance of success is provided.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses including inadequate segregation of duties and insufficient written policies.
- Subsequent Events: Between July 1 and July 28, 2025, the company raised an additional $1.6 million in net proceeds via ATM offerings.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance against the burn rate to estimate the runway before additional financing is required.
- Stock-Based Compensation: Review the magnitude of non-cash stock-based compensation ($3.1 million YTD 2025) and its impact on future dilution.
- Related Party Liabilities: Confirm the status of the $306,281 deferred compensation and $82,852 in unreimbursed expenses owed to related parties.
- Remediation Plan: Assess the specific steps management is taking to remediate the material weaknesses in internal controls over financial reporting.
- ATM Availability: Monitor the remaining capacity under the current ATM agreement with H. C. Wainwright and the market price volatility affecting future raises.